UNSPSC 41131731: Thromboplastin generation test

In this classification a thromboplastin generation test is a device used to detect and identify coagulation factor deficiencies and coagulation inhibitors US FDA regulates Thromboplastin generation test under 21 CFR 864.7900 and under FDA product code GKQ.

UNSPSC 41131731 Thromboplastin generation test is a Commodity code, but the recent state and local opportunities tagged under it do not correspond to thromboplastin testing. Instead, they reflect a much broader procurement pattern centered on drug testing services, laboratory supplies, and forensic drug screening—activities that fall outside the nominal scope of this hematology-focused code. The issuing bodies span multiple jurisdictions including Texas counties (Collin County Community Supervision and Corrections Department, Texas Comptroller of Public Accounts Statewide Procurement Division), Georgia counties (Gwinnett County), North Carolina municipalities (City of Charlotte), New Mexico counties (Bernalillo County), Florida counties (Seminole County, Pinellas County), Oregon counties (Benton County) and state health authorities (State of Oregon), and a Wisconsin university system (University of Wisconsin-Madison). The work being solicited encompasses offender drug screening and specimen collection services, laboratory testing supplies for drugs-of-abuse analyzers, forensic DNA and controlled-substance detection reagents and equipment, occupational health screening, clinical laboratory services, urinalysis testing for treatment courts, clozapine psychiatric medication monitoring assays, and certified reference materials for forensic drug analysis. This is a significant mismatch—the code's nominal definition refers to a specific coagulation assay, whereas the actual procurement activity under this tag centers on substance-abuse testing and forensic drug analysis across public safety, healthcare, and treatment-court operations.

Representative recent opportunities include Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services (approximately 25,031 tests annually, estimated contract value $600,000, proposals due July 23, 2026), the Texas Comptroller of Public Accounts' IFB 304T-27-175A1.1 for proprietary chemical laboratory equipment and supplies including DNA analysis and direct ELISA kits for controlled-substance detection (50 line items, questions due October 5, 2026, bids due October 20, 2026), Gwinnett County, Georgia's RFQ for drug testing supplies compatible with a drugs-of-abuse analyzer system (proposals due October 14, 2026), Benton County, Oregon's RFP for urinalysis testing services to support the Family Treatment Court Program (proposals due July 7, 2026, work to begin by end of July 2026), and Pinellas County, Florida's ITQ 26-0305-ITQ for 131 line items of certified reference materials and drug standards for forensic drug analysis (proposals due April 23, 2026, delivery by June 1, 2026, funded through the Paul Coverdell Forensic Sciences Improvement Act Program). Geographic activity concentrates in Texas (multiple state and county solicitations), Florida (forensic laboratory procurement), and Oregon (treatment court and psychiatric medication monitoring), with additional recent postings in Georgia, North Carolina, and Wisconsin. The code shows no recent activity consistent with its nominal definition as a thromboplastin generation test.